Elite Pharmaceuticals, Inc.
specializes in the development of oral controlled release products, such as delayed, sustained, targeted and pulsatile release tablets, pellets, capsules, granules and powders.
The Company’s primary focus is in the therapeutic areas of pain management, allergy, cardiovascular and infection.
The Rodman & Renshaw 16th Annual Global
Live presentation on September. 9, 2014
at 2:55 PM Eastern
replay available until December 18, 2014
Recent Press Releases:
||Elite Pharmaceuticals Awarded Second Canadian Patent for Abuse Deterrent Drug Formulation
||ELITE PHARMACEUTICALS REPORTS SUCCESSFUL PIVOTAL BIOEQUIVALENCE STUDY FOR ABUSE-DETERRENT OXYCODONE PRODUCT ELI-201
||Elite Pharmaceuticals, Inc. Reports Financial Results for the Second Quarter of Fiscal Year 2015
Revenues increase by 8%
Conference Call Scheduled for Wednesday, November 19 at 11:00 AM EST
||ELITE PHARMACEUTICALS ANNOUNCES NEW MANAGEMENT APPOINTMENTS
||ELITE PHARMACEUTICALS RELEASES POSITIVE TOP LINE HUMAN ABUSE LIABILITY DATA FOR ELI-200, AN OPIOID ABUSE DETERRENT PRODUCT
HAL study compared subjective effects of drug liking, drug high and good drug effects between ELI-200 and the comparator formulation in non-dependent recreational drug users